90 related articles for article (PubMed ID: 12115651)
1. B cells engineered to express Fas ligand suppress pre-sensitized antigen-specific T cell responses in vivo.
Kosiewicz MM; Krishnan A; Worthington MT; Matriano JA; Ross WG
Eur J Immunol; 2002 Jun; 32(6):1679-87. PubMed ID: 12115651
[TBL] [Abstract][Full Text] [Related]
2. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells.
Zhang HG; Su X; Liu D; Liu W; Yang P; Wang Z; Edwards CK; Bluethmann H; Mountz JD; Zhou T
J Immunol; 1999 Feb; 162(3):1423-30. PubMed ID: 9973398
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous in vivo retrovirus-infected T and B cells, but not dendritic cells, mediate antigen-specific Fas ligand/Fas-dependent apoptosis of anti-retroviral CTL.
Rich RF; Cook WJ; Green WR
Virology; 2006 Mar; 346(2):287-300. PubMed ID: 16337984
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of lymphoid hyperplasia and hypergammaglobulinemia in lupus-prone mice (gld) by Fas-ligand gene transfer.
Hong NM; Masuko-Hongo K; Sasakawa H; Kato T; Shirai T; Okumura K; Nishioka K; Kobata T
J Autoimmun; 1998 Aug; 11(4):301-7. PubMed ID: 9776707
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL).
Drozdzik M; Qian C; Lasarte JJ; Bilbao R; Prieto J
Gene Ther; 1998 Dec; 5(12):1622-30. PubMed ID: 10023441
[TBL] [Abstract][Full Text] [Related]
6. Fas (CD95)/Fas ligand interactions regulate antigen-specific, major histocompatibility complex-restricted T/B cell proliferative responses.
Ozdemirli M; El-Khatib M; Foote LC; Wang JK; Marshak-Rothstein A; Rothstein TL; Ju ST
Eur J Immunol; 1996 Feb; 26(2):415-9. PubMed ID: 8617312
[TBL] [Abstract][Full Text] [Related]
7. Suppression of the cell-mediated immune response by a Fas-immunoglobulin fusion protein.
Shen Y; Young B; Lipman ML
Transplantation; 2006 Apr; 81(7):1041-8. PubMed ID: 16612282
[TBL] [Abstract][Full Text] [Related]
8. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
[TBL] [Abstract][Full Text] [Related]
9. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
[TBL] [Abstract][Full Text] [Related]
10. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive.
Kim SH; Bianco N; Menon R; Lechman ER; Shufesky WJ; Morelli AE; Robbins PD
Mol Ther; 2006 Feb; 13(2):289-300. PubMed ID: 16275099
[TBL] [Abstract][Full Text] [Related]
11. B lymphocytes mediate Fas-dependent cytotoxicity in MRL/lpr mice.
Bonardelle D; Benihoud K; Kiger N; Bobé P
J Leukoc Biol; 2005 Nov; 78(5):1052-9. PubMed ID: 16204618
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid factor B cell tolerance via autonomous Fas/FasL-independent apoptosis.
Warnatz K; Kyburz D; Brinson DC; Lee DJ; Von Damm A; Engelhart M; Corr M; Carson DA; Tighe H
Cell Immunol; 1999 Jan; 191(1):69-73. PubMed ID: 9918688
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
Kosiewicz MM; Alard P; Liang S; Clark SL
Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
[TBL] [Abstract][Full Text] [Related]
14. The role of Fas/FasL interactions in the regulation of B cell function.
Jacobson BA; Rothstein TL; Marshak-Rothstein A
Behring Inst Mitt; 1996 Oct; (97):185-99. PubMed ID: 8950476
[TBL] [Abstract][Full Text] [Related]
15. Changes in sensitivity of peripheral lymphocytes of autoimmune gld mice to FasL-mediated apoptosis reveal a mechanism for the preferential deletion of CD4-CD8-B220+ T cells.
Xiao S; Zhang X; Mann KK; Jodo S; Li L; Jarjour WN; Marshak-Rothstein A; Sherr DH; Ju ST
Int Immunol; 2004 May; 16(5):759-66. PubMed ID: 15096479
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL.
Kim SH; Kim S; Oligino TJ; Robbins PD
Mol Ther; 2002 Nov; 6(5):584-90. PubMed ID: 12409256
[TBL] [Abstract][Full Text] [Related]
17. Prevention of autoimmunity and control of recall response to exogenous antigen by Fas death receptor ligand expression on T cells.
Mabrouk I; Buart S; Hasmim M; Michiels C; Connault E; Opolon P; Chiocchia G; Lévi-Strauss M; Chouaib S; Karray S
Immunity; 2008 Dec; 29(6):922-33. PubMed ID: 19013083
[TBL] [Abstract][Full Text] [Related]
18. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion.
Nyhus JK; Wolford C; Feng L; Barbera-Guillem E
Gene Ther; 2001 Feb; 8(3):209-14. PubMed ID: 11313792
[TBL] [Abstract][Full Text] [Related]
19. Antigen-induced cell death of T effector cells in vitro proceeds via the Fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes.
Sobek V; Balkow S; Körner H; Simon MM
Eur J Immunol; 2002 Sep; 32(9):2490-9. PubMed ID: 12207333
[TBL] [Abstract][Full Text] [Related]
20. Role of Fas/Fas ligand-mediated apoptosis in murine contact hypersensitivity.
Xu B; Bulfone-Paus S; Aoyama K; Yu S; Huang P; Morimoto K; Matsushita T; Takeuchi T
Int Immunopharmacol; 2003 Jul; 3(7):927-38. PubMed ID: 12810350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
